EAM
SBFM

Empery Asset Management’s Sunshine Biopharma SBFM Stock Holding History

Empery Asset Management’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23
Closed -$1.1M – 80
2022
Q1 		$1.1M Buy
+23
New +$1.12M 5.19% 5

Other funds holding SBFM

BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
DWM
Dakota Wealth Management Palm Beach Gardens, Florida $4.62B AUM 33.09% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Empery Asset Management's SBFM Position: Q2 2022 in Review

Empery Asset Management sold out of Sunshine Biopharma (SBFM) in Q2 2022, closing a stake of 23 shares — an estimated $1.1M sold.

Empery Asset Management first reported a position in SBFM in Q1 2022 and held it in 1 quarter. The position peaked at $1.1M in Q1 2022. 6 funds tracked by Wall St. Rank hold SBFM as of Q2 2022.

  • Empery Asset Management reported no remaining Sunshine Biopharma position as of Q2 2022 after selling out during the quarter.
  • Empery Asset Management sold 23 Sunshine Biopharma shares in Q2 2022, an estimated $1.1M.
  • Empery Asset Management first reported a position in Sunshine Biopharma in Q1 2022 and held it in 1 quarter.
  • Empery Asset Management's Sunshine Biopharma position peaked at $1.1M in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2022.

Based on Empery Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.